发明申请
US20110294148A1 TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER
审中-公开
作为癌症标志物的基质金属蛋白酶1（TIMP-1）的组织抑制剂和用于癌症以前的病史的患者的最小残留疾病或复发性疾病的手术标记
- 专利标题： TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER
- 专利标题（中）： 作为癌症标志物的基质金属蛋白酶1（TIMP-1）的组织抑制剂和用于癌症以前的病史的患者的最小残留疾病或复发性疾病的手术标记
-
申请号： US13198519申请日： 2011-08-04
-
公开(公告)号： US20110294148A1公开(公告)日： 2011-12-01
- 发明人: Mads Nikolaj Holten-Andersen , Ib Jarle Christensen , Nils Brünner , Hans Jørgen Nielsen
- 申请人： Mads Nikolaj Holten-Andersen , Ib Jarle Christensen , Nils Brünner , Hans Jørgen Nielsen
- 申请人地址： DK Hvidovre DK Copenhagen
- 专利权人： HVIDOVRE HOSPITAL,RIGSHOSPITALET
- 当前专利权人： HVIDOVRE HOSPITAL,RIGSHOSPITALET
- 当前专利权人地址： DK Hvidovre DK Copenhagen
- 优先权： DK199900476 19990409
- 主分类号： G01N33/566
- IPC分类号： G01N33/566 ; G01N27/447 ; G06F19/00 ; G01N33/559
摘要：
The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.